Cambrex has initiated an expansion of its Charles City, Iowa facility to meet demand for contract active pharmaceutical ingredient (API) contract manufacturing. The company expects to invest between $45 million and $50 million during 2015, which includes a cGMP production facility and related supporting infrastructure. This project is expected to be completed in early 2016 and is designed to allow Cambrex to further expand cGMP capacity as future growth requires.

The new manufacturing facility will initially add a total of 70 cubic meters of glass-lined and hastelloy reactors ranging in size from 7 cubic meters to 16 cubic meters, along with 6-square meter hastelloy filter dryers to provide a flexible, multi-purpose configuration. The facility will be designed to handle potent APIs at an occupational exposure limit (OEL_ down to 1µg per cubic meter and will increase the company's cGMP manufacturing capabilities. The facility is also expandable with the ability to add additional capacity on a short timeline. The capacity is being added along with 45,000 square feet of new cGMP, temperature- and humidity-controlled warehouse space.

Source: Cambrex